Philadelphia Trust Co. Has $3.85 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Philadelphia Trust Co. decreased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 9.7% during the 4th quarter, HoldingsChannel.com reports. The fund owned 318,230 shares of the company’s stock after selling 34,132 shares during the period. Philadelphia Trust Co.’s holdings in Elanco Animal Health were worth $3,854,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ELAN. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. Jones Financial Companies Lllp lifted its position in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. grew its position in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after acquiring an additional 3,411 shares during the last quarter. MRP Capital Investments LLC acquired a new position in Elanco Animal Health during the fourth quarter worth about $61,000. Finally, Blue Trust Inc. lifted its holdings in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after acquiring an additional 1,894 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Insider Activity at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average cost of $10.90 per share, with a total value of $109,000.00. Following the purchase, the director now owns 101,459 shares in the company, valued at $1,105,903.10. This represents a 10.93 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.57% of the stock is owned by corporate insiders.

Elanco Animal Health Stock Down 0.8 %

Shares of NYSE ELAN opened at $8.64 on Friday. The company’s 50 day moving average price is $10.59 and its 200-day moving average price is $12.03. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a 52-week low of $8.03 and a 52-week high of $18.80. The company has a market capitalization of $4.29 billion, a P/E ratio of 21.60, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business earned $0.08 EPS. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Morgan Stanley lowered their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 26th. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a report on Friday, February 21st. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Finally, Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $15.17.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.